Olmedipin (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxomil, the active ingredient in Olmedipin, is an antihypertensive presented as a tablet for oral use. It treats high blood pressure and may be used in patients who require combined renin‑angiotensin system blockade and calcium‑channel modulation. GNH USA supplies Olmedipin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmedipin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmedipin combines the actions of two antihypertensive agents and is indicated for management of hypertension.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Chronic kidney disease with hypertension: provides blood‑pressure control that helps slow renal function decline. - Heart failure with reduced ejection fraction: used as part of combination therapy to improve outcomes. - Post‑myocardial infarction: assists in blood‑pressure management to lower the risk of recurrent events.

Olmedipin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Peripheral edema – swelling of the ankles or feet. - Headache – mild to moderate intensity. - Dizziness – especially when standing quickly. - Flushing – transient warmth and redness. - Fatigue – general tiredness. - Nasal congestion – stuffy nose.

Serious or Rare Side Effects: - Angio‑edema – rapid swelling of the face, lips, tongue or throat. - Severe hypotension – markedly low blood pressure causing fainting. - Hepatic injury – abnormal liver function tests or hepatitis. - Hyperkalemia – elevated potassium levels that may affect heart rhythm. - Acute kidney injury – sudden decline in renal function. - Myocardial infarction – rare occurrence of heart attack.

When using Olmedipin, clinicians should assess patient history and monitor relevant parameters.

- Renal impairment: adjust monitoring and consider dose adjustments. - Hepatic disease: use with caution and observe liver function. - Electrolyte imbalance: check potassium and sodium levels regularly. - Pregnancy: contraindicated in the second and third trimesters; avoid use. - Concomitant strong CYP3A4 inhibitors: may increase amlod1pine levels. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Olmedipin can interact with several medicines that affect blood pressure, electrolyte balance, or drug metabolism.

Major Interactions (Avoid): - ACE inhibitors or ARBs combined with aliskiren in diabetic patients – risk of renal dysfunction. - Potassium‑sparing diuretics – heightened risk of hyper‑kalemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole) – increased amlodipine exposure.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may reduce antihypertensive effect. - Diuretics (thiazide or loop): may potent of the blood‑pressure‑lowering effect. - Lithium : potential            ...